Acquisition Opportunity Galmed recently acquired Colospan Ltd., a commercial-stage medical device company addressing anastomotic leak complications in colorectal surgery. This expansion signals a broader clinical and product portfolio, presenting cross-sell and bundled solution opportunities to colorectal surgery stakeholders and hospital networks.

Pipeline Expansion Lead asset Aramchol is in a Phase 3 registrational study for NASH and fibrosis, with ongoing collaborations such as brain cancer research and Amilo-5MER for ulcerative colitis. This indicates multiple near-term and mid-term clinical milestones and potential licensing or co-development deals with larger pharma partners.

Strategic Partnerships Recent or ongoing collaborations with Tel Aviv University, Virginia Commonwealth University, and OnKAI point to a strong partner-sourcing approach. Leverage these networks to position joint development opportunities, co-funded trials, and academic-to-industry licensing deals.

Global Investor Readiness With funding of approximately $113M and revenue in the low to mid single digits, Galmed presents a path for strategic equity financings or milestone-driven partnerships to accelerate development, alongside potential co-investment with institutions and collaborators tied to Aramchol and Amilo-5MER programs.

Modalities and Markets Technologies span small molecule therapies, brain-penetrant formulations, and peptide-based therapies, creating opportunities across hepatology, neuro-oncology, GI inflammatory diseases, and surgical devices. This diversified modality footprint can enable multi-vertical outreach to pharma, biotech, and specialty care providers seeking integrated solutions.